ArticleAlimentary pharmacology & therapeutics2026
Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease-A Multicentre Study.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chronic viral hepatitis with concurrent metabolic dysfunction-associated steatotic liver disease: dual etiology challenges.Clinical and molecular hepatology · 2026Review
- Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease-A Multicentre Study.Alimentary pharmacology & therapeutics · 2026Article
- Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is associated with increased mortality in patients awaiting liver transplant (LT), but the impact of sarcopenia on cirrhosis progression remains under-evaluated.
aimsWe aimed to explore the relationship between sarcopenia and the risk of cirrhosis progression, mortality and hospitalisation in compensated and decompensated cirrhosis.
methodsSarcopenia was measured using the skeletal muscle index (SMI) obtained from abdominal CT imaging at the 3rd lumbar vertebra (L3). Progression of cirrhosis was defined by an increase in clinical stage from baseline using the D'Amico classification. Factors associated with progression or death, death alone and hospitalisation were evaluated with univariate and multivariate Cox regression models.
resultsOne thousand six hundred and twenty-four adult patients with cirrhosis from five centres across Europe, North America and Asia were included. Mean age was 54 ± 9 years, 26% of patients were female, 31% had compensated disease and mean MELD-Na was 15 ± 7. With separate analyses for compensated and decompensated cirrhosis, sarcopenia was independently associated with the risk of progression or death (aHR 1.43, 95% CI 1.14-1.79, p = 0.002) and death alone (aHR 1.55, 95% CI 1.19-2.03, p = 0.001) only in decompensated cirrhosis. Sarcopenia was independently associated with unplanned hospitalisation in both compensated (aHR 1.70, 95% CI 1-15-2.51, p = 0.010) and decompensated cirrhosis (aHR 1.32, 95% CI 1.08-1.63, p = 0.007).
conclusionsSarcopenia was independently associated with cirrhosis progression or death and death alone in decompensated cirrhosis. Future studies are needed to evaluate the possibility of slowing cirrhosis disease progression by reversing or preventing sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.